GlassScriptPhysician profile
Branden Hsu
NPI 1952342123
$68,953.41
in general payments reported to CMS, 2019-2025
45 companies · $6,435 in 2025
The $6,435 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,591 · 2020: $12K · 2021: $20K · 2022: $11K · 2023: $4,343 · 2024: $7,554 · 2025: $6,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $1,897 · Travel and Lodging: $67.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,367.50 |
| Food and Beverage | $1,897.09 |
| Travel and Lodging | $67.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $9,578.57 | 2020-2025 | Xpovio |
| Incyte Corporation | $8,227.94 | 2020-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $7,934.89 | 2019-2025 | Calquence, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $7,082.48 | 2019-2025 | Darzalex, Erleada |
| Genzyme Corporation | $5,901.37 | 2020-2025 | |
| Array Biopharma INC | $3,796.58 | 2020-2023 | Mektovi, Braftovi, Xalkori |
| Glaxosmithkline, LLC. | $2,927.51 | 2021-2025 | Ojjaara |
| Beigene USA, INC. | $2,846.66 | 2022-2025 | Brukinsa |
| Seagen INC. | $2,802.61 | 2019-2021 | |
| Global Blood Therapeutics, INC. | $2,593.12 | 2022 | |
| Celgene Corporation | $1,998.67 | 2019-2023 | Pomalyst |
| Kite Pharma, INC. | $1,700.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,682.61 | 2019-2023 | |
| Coherus Oncology, INC. | $1,650.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $1,429.64 | 2020-2025 | Opdivo |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $1,250.00 | 2021 | |
| Exelixis INC. | $778.29 | 2019-2020 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Alexion Pharmaceuticals, INC. | $550.00 | 2019-2022 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Pfizer INC. | $453.41 | 2021-2024 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Cardinal Health 110 LLC | $375.00 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $340.00 | 2021 | |
| Athenex Pharmaceutical Division, LLC | $325.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $232.09 | 2022-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Astrazeneca Uk Limited | $121.99 | 2025 | Calquence |
| Comsort, INC | $100.00 | 2019 | |
| Astellas Pharma US INC | $58.46 | 2023-2025 | Xtandi, Padcev, Xospata |
| Tempus Ai, INC | $51.12 | 2024-2025 | Xt Cdx |
| Gilead Sciences, INC. | $49.47 | 2021-2024 | Trodelvy |
| Eisai INC. | $35.02 | 2024-2025 | |
| Puma Biotechnology, INC. | $34.59 | 2023-2024 | |
| Immunocore Limited | $32.67 | 2024 | Kimmtrak |
| Amneal Pharmaceuticals LLC | $29.23 | 2025 | Alymsys |
| Amgen INC. | $27.95 | 2020 | |
| Fennec Pharmaceuticals, INC. | $25.94 | 2024 | Pedmark |
| Jazz Pharmaceuticals INC. | $24.32 | 2023 | |
| Boston Scientific Corporation | $20.65 | 2025 | Watchman Flx |
| Abbvie INC. | $20.31 | 2024 | |
| Merck Sharp & Dohme LLC | $19.88 | 2025 | Keytruda, Welireg |
| Genmab U.S., INC. | $19.47 | 2024 | Tivdak |
| Genentech USA, INC. | $14.30 | 2024 | Itovebi |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Branden Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.